IFP Advisors Inc Sells 2,013 Shares of AbbVie Inc. $ABBV

IFP Advisors Inc reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,930 shares of the company’s stock after selling 2,013 shares during the quarter. IFP Advisors Inc’s holdings in AbbVie were worth $13,319,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the fourth quarter valued at about $28,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID grew its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. bought a new position in AbbVie during the fourth quarter valued at about $31,000. Finally, WestEnd Advisors LLC increased its stake in AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Up 1.0%

Shares of ABBV opened at $251.20 on Friday. The company has a 50-day moving average price of $244.51 and a two-hundred day moving average price of $225.96. The stock has a market cap of $443.82 billion, a price-to-earnings ratio of 70.96, a P/E/G ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the company posted $2.97 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts expect that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong post-Humira growth: AbbVie reported first-quarter 2026 revenue of $15.002 billion, up 12.4% year over year on a reported basis and 10.3% operationally. Adjusted diluted EPS of $2.65 exceeded internal expectations despite a $0.41-per-share headwind from acquired in-process research and development costs, supporting confidence in the company’s ability to replace Humira-related sales. Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
• Positive Sentiment: Analyst support strengthened: Wolfe Research upgraded AbbVie, citing the company’s pipeline strength and valuation. BNP Paribas Exane also indicated that the stock could rise, adding to the bullish research tone. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation AbbVie Stock Price Expected to Rise, BNP Paribas Exane Analyst Says
• Positive Sentiment: Commercial and pipeline catalysts: AbbVie’s Botox filing and Canada’s reimbursement recommendation for UBRELVY in adult migraine treatment could expand revenue opportunities in aesthetics and neuroscience. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Neutral Sentiment: Updates on venetoclax in high-risk myelodysplastic syndromes and a completed Phase 3 Botox jawline study provide potential longer-term catalysts, but their financial impact depends on additional data, regulatory decisions, and commercialization. AbbVie’s Venetoclax Combo in High-Risk MDS
• Negative Sentiment: Erste Group Bank lowered its AbbVie earnings estimates, highlighting a counterpoint to the positive upgrades and potentially limiting near-term upside. Erste Group Bank Lowers Earnings Estimates for AbbVie

Wall Street Analyst Weigh In

A number of brokerages have commented on ABBV. Bank of America raised their price objective on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Wells Fargo & Company boosted their price objective on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, July 10th. Royal Bank Of Canada upped their target price on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. BNP Paribas Exane raised their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.50.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.